Inventor · disambiguated record
Kyle Seamon
Also filed as: SEAMON KYLE · SEAMON KYLE JEFFREY
21 granted patents·3 pending applications·279 citations·filing 2019–2023
96Inventor score
Top patents by PatentIndex Score
24 records- 0198US11053485B2MAD nucleasesINSCRIPTA INC·Filed 2020·Granted Jul 6, 2021·5 cites·6 claims
- 0298US10883095B1Mad nucleasesINSCRIPTA INC·Filed 2020·Granted Jan 5, 2021·11 cites·6 claims
- 0398US10876102B2Engineered enzymesINSCRIPTA INC·Filed 2020·Granted Dec 29, 2020·9 cites·23 claims
- 0498US10870841B1Nucleic acid-guided nucleasesINSCRIPTA INC·Filed 2020·Granted Dec 22, 2020·5 cites·10 claims
- 0598US10767169B1Nucleic acid-guided nucleasesINSCRIPTA INC·Filed 2020·Granted Sep 8, 2020·43 cites·12 claims
- 0698US10745678B1Nucleic acid-guided nucleasesINSCRIPTA INC·Filed 2020·Granted Aug 18, 2020·51 cites·2 claims
- 0798US10724021B1Nucleic acid-guided nucleasesINSCRIPTA INC·Filed 2020·Granted Jul 28, 2020·51 cites·10 claims
- 0898US10704033B1Nucleic acid-guided nucleasesINSCRIPTA INC·Filed 2019·Granted Jul 7, 2020·52 cites·8 claims
- 0998US10655114B1Engineered enzymesINSCRIPTA INC·Filed 2020·Granted May 19, 2020·11 cites·20 claims
- 1098US10640754B1Engineered enzymesINSCRIPTA INC·Filed 2020·Granted May 5, 2020·12 cites·14 claims
- 1197US11085030B2MAD nucleasesINSCRIPTA INC·Filed 2021·Granted Aug 10, 2021·3 cites·6 claims
- 1297US11008557B1Cascade/dCas3 complementation assays for in vivo detection of nucleic acid-guided nuclease edited cellsINSCRIPTA INC·Filed 2020·Granted May 18, 2021·5 cites·20 claims
- 1397US10604746B1Engineered enzymesINSCRIPTA INC·Filed 2019·Granted Mar 31, 2020·16 cites·10 claims
- 1495US11193115B2Mad nucleasesINSCRIPTA INC·Filed 2021·Granted Dec 7, 2021·2 cites·6 claims
- 1590US11174471B2Mad nucleasesINSCRIPTA INC·Filed 2021·Granted Nov 16, 2021·1 cites·6 claims
- 1688US11345903B2Engineered enzymesINSCRIPTA INC·Filed 2020·Granted May 31, 2022·1 cites·17 claims
- 1781US11359187B1Cascade/dCas3 complementation assays for in vivo detection of nucleic acid-guided nuclease edited cellsINSCRIPTA INC·Filed 2022·Granted Jun 14, 2022·0 cites·27 claims
- 1881US2022267747A1Cascade/dCas3 Complementation Assays for In Vivo Detection of Nucleic Acid-Guided Nuclease Edited CellsINSCRIPTA INC·Filed 2022·Application pending·0 cites
- 1980US11286471B1Cascade/dCas3 complementation assays for in vivo detection of nucleic acid-guided nuclease edited cellsINSCRIPTA INC·Filed 2021·Granted Mar 29, 2022·0 cites·22 claims
- 2079US11198857B2Cascade/dCas3 complementation assays for in vivo detection of nucleic acid-guided nuclease edited cellsINSCRIPTA INC·Filed 2021·Granted Dec 14, 2021·0 cites·20 claims
- 2179US2022049233A1Novel mad nucleasesINSCRIPTA INC·Filed 2021·Application pending·0 cites
- 2277US11807877B1CRISPR/Cas activity assays and compositions thereofNAT TECH & ENG SOLUTIONS SANDIA LLC·Filed 2019·Granted Nov 7, 2023·1 cites·24 claims
- 2377US11104890B1Cascade/dCas3 complementation assays for in vivo detection of nucleic acid-guided nuclease edited cellsINSCRIPTA INC·Filed 2021·Granted Aug 31, 2021·0 cites·30 claims
- 2464US2024277796A1Methods for inhibiting rasREVOLUTION MEDICINES INC·Filed 2023·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Kyle Seamon files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →